Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger von Moos

Showing results (81-90 of 129) with videos related to

Pageof 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2020
MRI and <sup>18</sup>FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE TrialHans-Georg Wirsching, Ulrich Roelcke, Jonathan Weller, et al.
British Journal of Clinical Pharmacology|July 13, 2022
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP)Eduard Schmulenson, Cédric Bovet, Regula Theurillat, et al.
Endocrine Connections|August 18, 2017
Phase I trial of the androgen receptor modulator CR1447 in breast cancer patientsMartin Zweifel, Beat Thürlimann, Salome Riniker, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 3, 2013
Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatmentDaniel C Betticher, Geoffrey Delmore, Urs Breitenstein, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 27, 2024
Prevention of taxane chemotherapy-induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single-centre study with intrapatient comparisonKristen Johnson, Barbara Stoffel, Michael Schwitter, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|August 9, 2015
Health resource utilization associated with skeletal-related events: results from a retrospective European studyJean-Jacques Body, João Pereira, Harm Sleeboom, et al.
Cancer|August 9, 2024
Identifying the drivers of overall rating of cancer care: Insights from the second wave of the Swiss Cancer Patient Experiences studyVladimir Jolidon, Manuela Eicher, Isabelle Peytremann-Bridevaux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)Thomas Ruhstaller, Miklos Pless, Daniel Dietrich, et al.
Clinical Breast Cancer|June 19, 2025
Final Overall Survival Analysis of the Phase II SAKK 21/12 Trial of Transdermal CR1447 in Patients With Metastatic Breast CancerMarcus Vetter, Lisa Holer, Karin Rothgiesser, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2024
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17Michael Mark, Patrizia Froesch, Katrin Gysel, et al.
Pageof 13

Showing results (81-90 of 129) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2020
MRI and <sup>18</sup>FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE TrialHans-Georg Wirsching, Ulrich Roelcke, Jonathan Weller, et al.
British Journal of Clinical Pharmacology|July 13, 2022
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP)Eduard Schmulenson, Cédric Bovet, Regula Theurillat, et al.
Endocrine Connections|August 18, 2017
Phase I trial of the androgen receptor modulator CR1447 in breast cancer patientsMartin Zweifel, Beat Thürlimann, Salome Riniker, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 3, 2013
Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatmentDaniel C Betticher, Geoffrey Delmore, Urs Breitenstein, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 27, 2024
Prevention of taxane chemotherapy-induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single-centre study with intrapatient comparisonKristen Johnson, Barbara Stoffel, Michael Schwitter, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|August 9, 2015
Health resource utilization associated with skeletal-related events: results from a retrospective European studyJean-Jacques Body, João Pereira, Harm Sleeboom, et al.
Cancer|August 9, 2024
Identifying the drivers of overall rating of cancer care: Insights from the second wave of the Swiss Cancer Patient Experiences studyVladimir Jolidon, Manuela Eicher, Isabelle Peytremann-Bridevaux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)Thomas Ruhstaller, Miklos Pless, Daniel Dietrich, et al.
Clinical Breast Cancer|June 19, 2025
Final Overall Survival Analysis of the Phase II SAKK 21/12 Trial of Transdermal CR1447 in Patients With Metastatic Breast CancerMarcus Vetter, Lisa Holer, Karin Rothgiesser, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2024
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17Michael Mark, Patrizia Froesch, Katrin Gysel, et al.
Pageof 13